New Antibiotic for Complicated Urinary Tract Infections.


I (Imbruvica), an orally administered kinase inhibitor, is now approved by the Food and Drug Administration to treat chronic graft-versus-host disease (GVHD) after other treatments have failed. This is the first drug approved specifically for chronic GVHD. Ibrutinib was previously approved for the treatment of certain types of chronic lymphocytic leukemia… (More)
DOI: 10.1097/01.NAJ.0000527483.55997.0a


Cite this paper

@article{Aschenbrenner2017NewAF, title={New Antibiotic for Complicated Urinary Tract Infections.}, author={Diane S Aschenbrenner}, journal={The American journal of nursing}, year={2017}, volume={117 12}, pages={22-23} }